Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
Rhea-AI Summary
Beta Bionics (Nasdaq: BBNX) plans to release its Q2 2026 financial results after market close on Wednesday, July 29, 2026. Management will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to review quarterly performance.
Positive
- None.
Negative
- None.
News Market Reaction – BBNX
In the Jul 1 session, BBNX gained 6.57%, reflecting a notable positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Earnings date notice | Neutral | +1.6% | Notice of upcoming Q1 2026 results and conference call timing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date announcements for BBNX have been followed by modest positive share moves.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2026 financial results after the financial markets close on Wednesday, July 29, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s second quarter 2026 performance.
The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BI3bd9f03fbd0f42bcb9f566c242240033.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
